RUBICON2026-04-15RUBICON2026-04-152026-04-15iso4217:INRxbrli:pureRUBICONRubicon Research LimitedNewAcquisition (including agreement to acquire)2026-04-152026-04-15Rubicon Research LimitedListed Entity (self)Arinna Lifesciences Limited7150000009580000043700000falsefalsefalsefalsePharmaceuticals This acquisition furthers Rubicon’s strategy of leveraging its IP and chronic products portfolio to unlock growth in key markets, particularly in the CNS therapeutic category which has always been a core focus area for Rubicon. Arinna’s sales and distribution network will provide Rubicon access to patients and prescribers in India for its differentiated offerings, including a strong pipeline of specialty products and drug-device combinations.NAfalseThe acquisition is expected to be completed within one month from the date of the signing of the transaction documents or by such other timelines as may be mutually agreed between the parties.CashThe transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt free basis. After accounting for necessary adjustments to the enterprise value of Arinna, the purchase consideration has been determined to be approximately INR 175.92 Crores for secondary acquisition of 85% equity shareholding in Arinna on a fully diluted basis at a price of approximately INR 158.53 per share. The final consideration remains subject to adjustments on the closing date.175920000000.850.85Arinna Lifesciences Limited (“Arinna”) is a branded pharmaceutical marketing company headquartered in Ahmedabad, India, engaged in the marketing of branded pharmaceutical products in the Indian domestic market. Arinna operates on a commercial model focussed on the CNS / neuro-psychiatric therapeutic segment, with a product portfolio spanning antiepileptics, antidepressants / thymoleptics, antipsychotics among others. Arinna markets its products with a dedicated field force calling on prescribers across India.2013-08-29IndiaNote: Due to technical limitation in the XBRL, we have answered "No" to the question (1) whether the same is done at "arms length"? (2) whether special resolution is passed/proposed?. Kindly read the same as Not Applicale. Turnover for last three years is FY 2024-25: INR 71.50 crores; FY 2023-24: INR 65.14 crores; and FY 2022-23: INR 60.06 crores.